Alife Health, the startup that is working towards building artificial intelligence (AI) tool that will advance in-vitro fertilization (IVF), gains $22 million in its Series A round.
The startup’s funding round was co-led by Deena Shakir of Lux Capital, Rebecca Kaden of Union Square Ventures and Anarghya Vardhana of Maveron. They have also been invested by Springbank Collective, IA Ventures and more.
Successful pregnancies from IVF depends upon multiple clinical decisions and is expensive and inaccessible for many people. Alife Health aims to strengthen and enhance IVF decision making by using personalised insights related to patients’ health. This data will also bring down the costs and increase the chance of success.
They have partnered with multiple clinics and physicians to improve the result for the patients. Their AI software is transforming the anachronism of fertility care. Their app also helps patients understand via educational health content, reminders for medicines and lab appointments amongst other features.
Founded by Paxton Maeder-York in 2020, the venture will use the new funds to launch its 2 products in the market and start clinical trials for the next one. Prior to this, they had raised $9.5 million in their seed round in 2021.